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EXPERIMENTAL 
Raw Data 
The raw data were either obtained from the original articles or obtained 
after request from the senior author. The drugs and references are as 
follows: ampicillin (1), diazepam (2), diphenhydramine (3), nortriptyline (4), 
phenytoin (5), tranexamic acid (6), warfarin (7), acetylsalicylic acid and 
salicylic acid (8), cefazolin (9), clindamycin phosphate and tobramycin 
(10,11), digoxin (12-16), griseofulvin (17), pentobarbital (18), pindolol 
(19), quercetin (20), spectinomycin (21), sulfisoxazole (22), and cephalexin 
(23). 
Methods 
For acetylsalicylic acid (8), diazepam (2), digoxin (12), griseofulvin (17), 
and salicylic acid (8), the coefficients and exponents of the polyexponential 
equations which the original authors had fitted to the data were employed. 
In all other cases, the procedure was as follows. Each set of plasma (or 
serum) concentration-time data observed either following bolus intraven- 
ous injection or subsequent to the termination of a constant-rate intraven- 
ous infusion was evaluated by the program CSTRIP (24) and a digital 
computer. The operator requested the program to print out the optimum 
polyexponential equation for one, two, three, and four exponential-terms. 
The "optimum," decided by the program, is the equation which arises from 
the grouping of the points for each exponential term which yields the 
minimum sum of squared deviations. For each data set, the operator then 
decided the appropriate number of exponential terms for a nonlinear 
least-squares fit. The latter was usually decided by the regression analysis of 
C vs. C and use the percentage improvement in r22, the coefficient of 
determination, which is printed out by the program; criteria used in the 
decision are shown in Table I. 
In practice, in most cases the decision was made quite easily, since, for 
example, if the optimum number of terms was two, the r 2 value for the 
two-term equation was higher than for a three-term or four-term equation. 
Sometimes an asymptotic r22 value was reached at the two-term level such 
that the r 2 values for the two-term, three-term, and four-term polyexponen- 
tial equations were the same. Each set of data was then fitted to the 
appropriate polyexponential equation using the program NONLIN (25) and 
a high-speed digital computer; the preliminary estimates of the coefficients 
and exponents used as input for NONLIN were those obtained from the 
program CSTRIP. If there was any doubt about the required number of 
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Table 1. G o o d n e s s - o f - F i t  Cr i te r ia  to E s t i m a t e  the  N u m b e r  of Exponen t i a l  T e r m s  N e e d e d  
r22 value for 
polyexponential equation 
with n terms a 
Percent improvement in r22 value 
required to choose a 
polyexponential equation 
with n + 1 terms 
r~ -< 0.75 
0.75 < r ~ -  0.90 
0.90 < r 2 --- 0.95 





a 2  
r 2 = coefficient of  d e t e r m i n a t i o n  
= 1 - ( C / -  Q ) 2  C~  - rn 
i=1 t i =  1 U i=1 
where rn is the number of plasma concentration measurements. 
exponential terms needed, then NONLIN least-squares fits with both n and 
n + 1 terms were obtained and the F test described by Boxenbaum et al. (26) 
was used. In each fitting, the squared deviations were weighted according to 
the reciprocals of the observed concentrations. All fittings were performed 
to the general polyexponential equation 1 for bolus intravenous data and to 
equation 2 for post-constant-rate infusion data. 
Cp= ~ C~e -A'' (1) 
i=1 
C o= ~ Y~e -h/ (2) 
i=1 
In equations 1 and 2, Cp symbolizes the plasma (or serum) concentration at 
time t, C~ is the coefficient of the ith exponential term for bolus intravenous 
data, Y~ is the coefficient of the ith exponential term for post constant-rate 
intravenous infusion data, and,~i is the exponent of the ith exponential term. 
If only one infusion had been administered over T hours, then the 
equation of the form of equation 2, obtained from postinfusion data, was 
converted to the corresponding equation 1 (simulating the situation if the 
total infused dose had been given as a bolus intravenous injection) by use of 
+A.T C~ = hiTY~/(e ' - 1) (3) 
Such a correction of the coefficients should be made even though only very 
short infusions have been administered. Several authors (6, 18, 20) failed to 
adjust the coefficients by means of equation 3 (or did not fit data to an 
equation which was appropriate for an infusion), and hence all their 
reported pharmacokinetic parameters were subject to error. 
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In the case of nortriptyline (4), multiple infusions were administered. 
Five infusions, each containing 11.4 mg of nortriptyline hydrochloride in 
25 ml of saline, were given over 10-rfiin periods with intervals of 5 min 
between infusions. In this case, Cp is given by 
Cp --i~=lLAiOq[ ~" [ Ci ~[e+Xa-1][e+X'm'~+--q'-l][e +xi (p+q) -  1] ke+X't*--e+X'm'(p+q)}] e-xit 
= ~ Z, e -x'' (4) 
i=1 
where Zi represents everything within the square brackets and the coeffi- 
cient is obtained by fitting postinfusion data. Equation 5 was then used to 
convert the Z/values to C~ values: 
ci = ,~ioqz,/ {P,} (5) 
where {P~} represents everything in the same type of braces in equation 4. In 
equation 4, q = 10 min (0.166 hr) and is the duration of each infusion; p = 5 
min (0.083 hr) and is the interval between infusions, p +q = 0.25 hr; m '=  4 
and is the number of p+q periods; t* = 1.166 hr= ( 0 -  1) (p+q)+q; 0 = 5 
and is the number of infusion periods; and t is the time from the start of the 
first infusion. 
The pharmacokinetic parameters were calculated using equations 6- 
11, reported by Wagner (27). 
i--1 
Vdss = D G/A C~/A~ (7) 
i= l  i -1  
gdarea = D/( ~l i~=l Ci/l~i) (8)  
Vdext = D/C1 (9) 
/ i Clp = D/ i=1 
tl/2 = 0.693/A 1 (11) 
In equations 6-11, D is the intravenous dose; C1 and h I a r e  the 
coefficient and exponent, respectively, such that h 1 is the smallest of the hg's 
of the polyexponential equation; Vp is the volume of the plasma (reference) 
compartment, Vass is the volume of distribution steady state; Vearea is that 
volume which, when multiplied by Cp in the log-linear phase (when only 
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C1 e -~lt is mak ing  a significant con t r ibu t ion  to Cv), is equal  to the a m o u n t  of 
drug in the body,  and  also such that  Clp = Vd . . . .  " h i ;  Vaext is the ext rapo-  
lated vo lume of d is t r ibut ion;  f l  n is the p lasma (or serum) c learance;  and  tl/2 
is the appa ren t  e l imina t ion  half-life. 
In  order  to avoid ar i thmet ic  errors,  equa t ions  6 -11  were p r o g r a m m e d  
on  an electronic  calculator.  Inpu t  was the dose and the coefficients and  
exponen t s ;  ou tpu t  was the le f t -hand  sides of equa t ions  6 -11  in numer ica l  
form. In  addi t ion,  the s tudents  calculated the pa ramete r s  separately,  provid-  
ing an addi t ional  check on  accuracy. 
R E S U L T S  
The n u m b e r s  of exponent ia l  terms used in the N O N L I N  fittings are 
summar ized  in Table  II. 
Table H. Number of Exponential Terms in Polyexponential Equations 
Number of data sets 
giving the 
indicated number of 
exponential terms 
Coefficients and 
Drug 1 2 3 exponents used 
Ampicillin a 8 T ~ 
Diazepam a 4 O a 
Diphenyhydramine b 2 T 
Nortriptyline b 4 T 
Phenytoin a 6 T 
Tranexamic acid b 2 T 
Warfarin a 9 T 
Tobramycin b 2 3 T 
Acetylsalicylic acid a 6 O 
Cefazolin a 5 T 
Clindamycin phosphate b 2 8 T 
Digoxin ~'b 18 T(2), O(16) 
Griseofulvin a 8 O 
Cephalexin b 8 T 
Pentobarbital b 5 T 
Pindalol b 2 3 T 
Quercetin b 6 T 
Salicylic acid 4 O 
Spectinomycin a 5 T 
Sulfisoxazole a 7 T 
~Bolus intravenous data evaluated. 
bPost constant-rate intravenous infusion data evaluated. 
CT = This study (means coefficients and exponents obtained by methods outlined in this article). 
ao  = Original (means that the coefficients and exponents reported in the original article were 
used). 
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In all cases reported, the NONLIN fits of individual data sets were 
excellent as judged by the r 2 values obtained: 
r~ = 1 - (C / -  C/) 2 C 
i 1 i = 1  
These usually exceeded 0.995. Several of the data sets of clindamycin 
phosphate in subjects under dialysis and in uremic subjects and of pentobar- 
bital fell in the region 0.988 < r 2 < 0.995. 
The data of subject 3, given cefazolin (9), were excluded, since the fit 
was not good (r~ = 0.861, Corr = 0.982), particularly at the tail end of the 
curve. 
Table III lists doses and pharmacokinetic parameters for eight drugs 
where data came from articles which listed the body weights of the individual 
subjects or patients. For these eight drugs, the volumes are given in liters/kg 
and the clearance in liters/(kg• hr); this is a distinct advantage since such 
parameters usually have smaller coefficients of variation than corresponding 
values expressed in liters and liters/hr, respectively. 
Tables IV and V list doses and pharmacokinetic parameters of 12 drugs 
where the data came from articles which did not list the body weights of 
individual subjects. Hence for these drugs volumes are given in liters and 
clearances in liters/hr. Tables III-V also list the number of subjects or 
patients for which data were evaluated, the type of subjects or paffents, and 
the mean, range, and coefficient of variation of each estimated parameter. 
The data given in Table IV for digoxin were calculated using the 
coefficients and exponents of biexponential equations reported by Koup et 
al. (12); these were obtained by the simultaneous fitting of both serum 
concentration and urinary excretion data. The individual subject values 
calculated in this study are listed in Table VI, along with variance ratios (F 
values) and results of paired t tests comparing bolus intravenous and 
infusion methods. It should be noted that paired t tests are valid even when 
the variances are not homogeneous (i.e., the F value is significant at 
p -< 0.05). Table VII lists the digoxin pharmacokinetic parameters obtained 
from postinfusion data of Wagner et al. (16). Table VIII lists (for the first 
time) the apparent elimination half-lives of digoxin estimated from terminal 
oral data following digoxin tablets (Burroughs & Wellcome) in the study of 
Wagner et al. (16). 
DISCUSSION 
There is no doubt that the method of data analysis used in this article 
results in improved parameter estimates. However, they are still potentially 
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Table VII. Pharmacokinetic Parameters of Digoxin Calculated from the Coeffi- 
cients and Exponents of Biexponential Equations Fitted to the Postinfusion Data 
of Wagner eta/. (16) 
Subject 
Parameter 1 2 Average 
~a (liters) 90.8 69.0 79.9 
~s (liters) 739 759 749 
Va .... (liters) 813 842 828 
Cln (liters) 10.7 12.0 11.4 
tlz2 (hr) 52.5 48.8 50.7 ~ 
AUC [(ng/ml) x hr] 44.6 41.8 43.2 b 
The average and range from the data of Koup et al. (12) was 42.1 (33.0-53.3) hr. 
bThe average for the 0.75-mg dose from the data of Koup et al. (12) was 64.3, 
which is equivalent to (0.5/0.75) x 64.3 = 42.9 for a 0.5-mg dose, hence agree- 
ment is excellent. 
Table VIII. Apparent Elimination Half-Lives 
of Digoxin Estimated from Digoxin Plasma 
Concentrations in the 24-96 hr Time Range 
and 0.04-0.3ng/ml Concentration Range 
Following Oral Administration of Lanoxin 
Tablets in the Study of Wagner et al. (16) 









Mean 43.3" (38.3) b 
C.V. (%) 41.1 
~The average (and range) in the intravenous 
study of Koup et al. (12) was 42.1 (33.0- 
53.3) hr, hence agreement is excellent. 
bValue in parentheses is the harmonic mean 
half-life. 
one  of the be t te r  programs for non l i nea r  analysis, bu t  is still subjec t  to false 
min ima.  Fell  and  Stevens (28) showed that  the N O N L I N  program resul ted 
in relat ively poor  est imates of the pa ramete r s  f rom data  der ived for one-  and  
t w o - b o d y - c o m p a r t m e n t a l  models.  The  use of r 2 for select ion of the n u m b e r  
of exponent ia l  terms and as a cr i ter ion of fit is subject  to er ror  since it is a 
measure  of overall  fit to the model .  
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Variability of Parameters 
Of the volumes V~ss, Vd ..... and Vaext, there is a general tendency for 
the coefficients of variation (C.V.) to increase in the order given, as well as 
the magnitudes of the volumes. That is, in general, Vdss not only is the 
smallest of these three volumes but also has the smallest C.V. This is 
fortunate since Vd~s is probably the most useful volume pharmacokineti- 
cally. The C.V. of Vd~ is less than the C.V. of Vd . . . .  for ampicillin, 
phenytoin, digoxin, griseofulvin, cephalexin, spectinomycin, and sulfisox- 
azole. The C.V. of Vd~ is approximately equal to the C.V. of Va . . . .  for 
diazepam, nortriptyline, warfarin, tobramycin, ASA, clindamycin phos- 
phate, pentobarbital, quercetin, and salicylic acid. 
The C.V. of CIp is greater than the C.V. of Vds~ for phenytoin, warfarin, 
digoxin, griseofulvin, pentobarbital, and quercetin. The C.V. of Clp is 
approximately equal to the C.V. of Vds~ for ampicillin, diazepam, nortrip- 
tyline, tobramycin, and clindamycin phosphate. The C.V. of Va~ is greater 
than the C.V. of Clp for ASA, cefazolin, pindolol, salicylic acid, spectinomy- 
cin, and sulfisoxazole (see Tables III-V). 
As pointed out earlier by Koup et al. (12), the C.V. of each phar- 
macokinetic parameter when digoxin was given by intravenous infusion is 
less than the corresponding C.V. when the drug was given by bolus intraven- 
ous injection (see Table VI). The variance ratios for bolus/infusion are 
significant (p --< 0.05) for 6-day urinary excretion, Valse, and Vdarea, but are 
not significant (p >0.05) for Vp, Clp, tile, and AUC. 
The variabilities of the pharmacokinetic parameters for tobramycin 
(Table III) and clindamycin phosphate (Table IV) in chronic renal patients 
undergoing dialysis are quite large, indicating considerable patient-to- 
patient variability. 
V d  e x i  
The extrapolated volume of distribution, Vaext, is probably the most 
common "volume of distribution" reported in the medical literature, yet it is 
the most inappropriate volume from a pharmacokinetic standpoint. Many 
assume that Clp = Wdex t  9 h l ,  but this has no foundation in pharmacokinetic 
theory. If the model is the simple one-compartment open model, then 
Vaext = Vdarea = Vdss and the clearance is equal to Vdext" hi. However, in all 
other cases Clp = Vdare~ " ~ 1" Hence, in most cases, the only time that Vdext is 
useful in a pharmacokinetic sense is when Vdext is only slightly larger than 
W d a r e  a and can be used as an estimate of Vaar~a. Of the 20 drugs studied, this 
approximation holds for only seven drugs (35%), namely for nortriptyline, 
tranexamic acid, warfarin, tobramycin, griseofulvin, pentobarbital, and 
salicylic acid (see Tables III-V). For the other 13 drugs, Vd~xt is of little use 
pharmacokinetically, except as noted below (see equation 17). 
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Use of Equations 3-5 
Readers' attention is drawn to the importance of applying equations 
3-5 to infusion data, even though constant-rate infusions are given over only 
a few minutes. A bolus injection in the pharmacokinetic sense means 
injection of the entire dose all at once at zero time, and the bolus intravenous 
equations have been derived with that assumption. In applying equation 3, 
the biggest difference in the Y~ 's and corresponding C~'s will occur with I12 
and C2 for a biexponential equation and in Y2 and C2 and Y3 and C3 for a 
triexponential equation. Also, if the investigator wishes to give a short 
infusion for safety purposes, the infusion should be administered at a 
constant rate and the infusion time accurately determined for each subject, 
so that equation 3 may be applied correctly. 
Reporting Body Weights 
It is a distinct advantage to report the body weights of individual 
subjects or patients in pharmacokinetic papers. The C.V.'s of the various 
pharmacokinetic parameters are almost always lower when corrections have 
been made for body weight than when they have not. This was tested with 
the drugs given in Table III and found to be true, and that is why the volumes 
are expressed in units of liters/kg and the clearances in liters/(kg x hr). Thus, 
if one is going to make estimates for a particular subject or patient from the 
tabled numbers, the body weight corrected value multiplied by the particu- 
lar patient's body weight will provide a better estimate of a mean value and 
the possible range of the value. It is suggested that journal editors accept 
pharmacokinetic articles only when individual body weights have been 
listed. The senior author of this article also believes that all raw data should 
be included in an article, particularly when they are intravenous data. 
Showing data in graphical form does not allow future reevaluation of data, 
such as is done in this article. It is really the raw data which have archival 
value, not someone's interpretation of the data. Theory and methods change 
with time, and reevaluation of data is often necessary at some later date. In 
the present instance, the senior author believed such a comparison of 
pharmacokinetic parameters should be done only when all data were 
evaluated by uniform methods. 
Number of Exponential Terms 
The type of data evaluated (i.e., either bolus intravenous or postinfu- 
sion) and the number of exponential terms used in the fittings are sum- 
marized in Table II. The table also indicates whose exponents and coeffi- 
cients were used in applying equations 6-11. 
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It should be noted that the same number of exponential terms are not 
always required to fit each member's data in a given panel administered a 
given drug. In the case of tobramycin, clindamycin phosphate, and pindolol, 
two data sets for each drug required only one exponential term, while the 
remainder required two exponential terms. We evaluated the phenytoin 
data of Gugler et al. (5) with triexponential equations, whereas the original 
authors used biexponential equations. Although the data evaluated for both 
phenytoin and salicylic acid fit the linear model at the low doses employed, it 
should be realized that these drugs obey Michaelis-Menten kinetics at 
higher doses. 
Digoxin 
Koup et al. (12) stated: "Urinary excretion data are essential for proper 
pharmacokinetic analysis of digoxin disposition and reveal a slower elimina- 
tion rate than that suggested by earlier studies which determined only serum 
concentrations." This statement is true for the earlier study of Kramer et al. 
(13), but not for the earlier study of Wagner etal. (16). The reason lies in the 
assay method published by Stoll et al. (29), which showed that lower plasma 
and serum levels of digoxin can be measured than those reported by either 
Kramer et al. (13) or Koup et al. (12). The pharmacokinetic parameters, 
particularly C1 m tl/2, and AUC, estimated from the plasma digoxin concent- 
rations after bolus intravenous administration in the study of Wagner et al. 
(16), shown in Table VII, are very similar to those obtained from the data of 
Koup et al. (12), shown in Table VI. Also, the apparent elimination 
half-lives of digoxin, not formerly reported but now shown in Table VIII, 
which were estimated from plasma digoxin concentrations measured by 
radioimmunoassay (29) following oral dosing with digoxin (Burroughs & 
Welcome tablet) are essentially the same as those reported by Koup et al. 
(12). As indicated by the table heading of Table VIII, the log-linear phase of 
digoxin elimination does not commence until about 24 hr, when the digoxin 
concentration is about 0.3 ng/ml, requiring a more sensitive assay than the 
routine radioimmunoassay and sampling each day in the 24-96 hr range 
after a single dose. In the studies of Kramer et al. (13), digoxin concentra- 
tions were measured down only to about 0.5 ng/ml, and in the studies of 
Koup et al. (12) concentrations in serum were measured down only to about 
0.3 ng/ml. 
Greenblatt et al. (14) recommended use of digoxin given by slow 
infusion over a 1-hr period and 6-day urinary excretion of apparent digoxin 
as bioavailability standard. Table VI, derived from the data of Koup et al. 
(12), indicates that mean 6-day urinary excretion of apparent digoxin was 
566 ~g for bolus and 610 #g for infusion; the 8% difference is significant 
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(0.05 > p  > 0.02) by paired t test. However, in both cases the C.V.'s are very 
small, being 7.8% for bolus and 3.4% for infusion. It should also be noted 
that the total AUC (obtained by integrating the polyexponential equations 
between the limits of 0 and ~)  averages 71.1 for bolus and 57.5 for 
infusion--a 24% difference, which did not test significant (0.10 > p > 0.05). 
Stoll and Wagner (15) pointed out that the bolus-infusion difference in 
6-day urinary excretion could be caused by the nonspecific radioimmunoas- 
say used (26) and the higher ratio of metabolites/digoxin in urine than in 
plasma. 
USE OF THE PHARMACOKINETIC PARAMETERS 
Baseline Data for Disease State Studies 
Most of the tabled values were calculated from data obtained when 
normal volunteers were given the drugs intravenously. Hence they may 
serve as baseline data for comparison purposes with similar values estimated 
from data obtained after administration of the same drugs intravenously to 
patients with various specific diseases. 
Constant-Rate Intravenous Infusion Therapy 
The mean values of the parameters may be most useful for initiating 
therapy with one of the drugs in a given patient. Some examples are given 
below, but these are not intended to be exhaustive or complete. 
1. A safe method for rapidly achieving a desired steady-state plasma 
concentration, C'p ', for drugs whose plasma concentration is describable by a 
biexponential equation was given by Wagner (30). The solution is such that 
the steady state is achieved as rapidly as possible after a final infusion rate is 
commenced. The method involves administration of two consecutive 
constant-rate infusions--one at a rate Q1 over T hours, and the second at a 
rate Qz starting at T hours and maintained as long as steady state is desired. 
The needed infusion rates are calculated with equations 12 and 13, using the 
nomenclature of this article. Suggestions for choosing the time Twere given 
in the original article (30). The method was later generalized by Vaughan 
and Tucker (31). 
O2 = CIp 9 Cf~ ~ (12) 
Oi = O 2 / ( 1 - e  ~,T) (13) 
The mean values of the exponents, ht, h2, and k3, obtained in the fittings 
reported in this article are shown in Table IX. 
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Table IX. Mean Values, A 1, A 2, and A 3, and Coefficients of Variation 
Drug A-~(hr -1) C.V.(%) A~(hr -1) C.V.(%) A 3(hr -1) C.V.(%) 
ASA 2.82 11 15.0 17 - -  - -  
Ampicillin 0.616 37.7 3.54 69.7 - -  - -  
Cefazolin 0.392 14.8 5.15 57.9 - -  - -  
Cephalexin 0.473 56.1 3.15 73.2 - -  - -  
Clindamycin 
phosphate 
Dialysis 0.247 66.8 3.31 - -  - -  - -  
Uremics 0.133 70.0 0.880 79.1 - -  - -  
Diazepam 0.023 13.8 0.411 60.1 8.42 111.0 
Digoxin 0.017 18.0 1.99 16.5 - -  - -  
Diphenhydramine 0.149 - -  7.7 - -  - -  - -  
Griseofulvin 0.054 30.0 0.67 28 - -  
Nortriptyline 0.0329 31.3 1.97 7.7 - -  - -  
Pentobarbital 0.0153 43.9 2.15 35.6 - -  - -  
Phenytoin 0.0399 16.0 0.563 71.5 6.44 68.1 
Pindolol 0.224 23.1 1.19 56.3 - -  - -  
Quercetin 0.740 65.3 14.7 69.8 - -  - -  
Salicylic acid 0.155 10.3 11.4 22.3 - -  - -  
Spectinomycin 0.454 35.8 7.24 72.9 - -  - -  
Sulfisoxazole 0.115 27.8 0.808 75.0 - -  - -  
Tobramycin 
(dialysis) 0.0513 39.4 0.881 25.5 - -  - -  
Tranexamic acid 0.735 - -  26.6 - -  - -  - -  
Warfarin 0.0254 49.5 1.94 66.4 - -  - -  
E x a m p l e  1: S u p p o s e  o n e  w i s h e d  to  a t t a i n  a s t e a d y - s t a t e  s e r u m  c o n c e n -  
t r a t i o n  of  a m p i c i l l i n  o f  2 5 / z g / m l  i n a  7 0 - k g  m a n .  T h e n ,  Cp s =  2 5 ;  f r o m  
T a b l e  IX___under a m p i c i l l i n  w e  o b t a i n  A1 = 0 . 6 1 6  h r  -~ a n d  f r o m  T a b l e  I I I  w e  
o b t a i n  Clp = 0 . 2 8 9  l i t e r s / ( k g x  hr) .  L e t  T = 0 .5  hr .  T h e n  s u b s t i t u t i n g  t h e s e  
v a l u e s  i n t o  e q u a t i o n s  12 a n d  13 g ives  
Q2 = ( 0 . 2 8 9 ) ( 7 0 ) ( 2 5 )  = 5 0 6  m g / h r  (14)  
Q1 = 5 0 6 / ( 1  - e -(~176 = 1 9 0 9  m g / h r  (15)  
T h u s  t h e s e  e s t i m a t e s  s u g g e s t  a n  in i t i a l  i n f u s i o n  r a t e  o f  a b o u t  1 9 0 0  m g / h r  f o r  
89 h r ,  t h e n  a n  a b r u p t  c h a n g e  to  a n  i n f u s i o n  r a t e  o f  a b o u t  5 0 0  m g / h r .  
2. A l t e r n a t i v e  m e t h o d  o f  c a l c u l a t i o n :  T h e  t h e o p h y l l i n e  e x a m p l e  u s e d  
b y  W a g n e r  (32)  is e m p l o y e d  f o r  i l l u s t r a t i o n  p u r p o s e s .  F o r  t h i s  e x a m p l e ,  t h e  
p a r a m e t e r  v a l u e s  w e r e  Clp = 0 . 0 8 6 4  l i t e r s / ( k g x  h r ) ,  C~p = 10  t z g / m l ,  Vp = 
0 . 2 7 7  l i t e r s / k g ,  Vas~ = 0 . 5 2 0  l i t e r s / k g ,  V, lext = 0 . 5 4 8  l i t e r s / k g ,  h i  = 0 . 1 6 2  
h r  -~, k2 = 5 . 9 9  h r  -~, a n d  T = 0 .5  hr .  T h e  b o l u s  l o a d i n g  d o s e ,  DL, is g i v e n  b y  
B o l u s  Om = Vd~" Cp s = ( 0 . 5 2 0 ) ( 1 0 )  = 5 . 2 0  m g / k g  (16)  
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However,  it is not usually safe to give the loading dose all at once at zero 
time, then start the infusion at the same time. Let  us assume we wish to give a 
loading dose over 0.5 hr. Then we must calculate how much of the bolus DE 
is lost in 0.5 hr, then add this amount  to the bolus DE to get the correct 
loading dose to administer as an infusion over 0.5 hr. 
One can "synthesize" the typical bolus intravenous equation using 
equation 17, reported by Wagner (30): 
G = ~d~t] Vp Vae,a] C1 + C2 e-%' 
(17) 
The matching of coefficients indicates that C1 =Di.v./Vdext and C2 = 
(Di.,,./Vp)(1- Vp/Vd~xt). Substitution of the values for theophylline and 
using Di.v. = 5.55 mg/kg (value which was formerly calculated which had to 
be given at the rate Q1) gives 
Cp = 10.128e -~ + 9.908e -5'99' (18) 
For a constant-rate infusion over 0.5 hr, the coefficients, X1 and Xz, are 
given by 
Xa = C1/,~ T = 10.128/[(0.162)(0.5)] = 125.0 (19) 
X2 = Cz/AzT = 9.908/[(5.99)(0.5)] = 3.31 (20) 
Hence during the 0.5-hr infusion the plasma concentration, C~p ur, will be 
given by 
C~p ur  --~ 125.0(1 - e -o.162t) -t-- 3.31(1 - e -5.99t) 
= 128.31 - 125.0e -~ - 3 . 3 1 e  -5"99t (21) 
The amount  eliminated in 0.5 hr, 0.5 A e  , is given by 
f0 "5 A e 0.5 = Clp C~p ur dt 
=0.0864[(128.31)(0.5)  - 0.---~ (1 - 125.0 J e _(o. 162)(o.5)  
3.31 ] 
- 5.9----9 (1 - e-(5'99~(~ = 0.31 mg/kg (22) 
Hence the total needed loading dose is given by 
Total Dc bolus DE " - -~  = + A e  = 5 .20+0.31 = 5.51 mg/kg (23) 
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By the method of Wagner (27), the Q1 rate obtained was 
11.1 mg/kg /hr  for T = 0 . 5 h r .  Thus in 0 .5hr  the dose delivered was 
5.55 mg/kg, which is essentially the same as the total DL of 5.51 mg/kg 
calculated above. Hence the method of Wagner (27) compensates for the 
drug lost from the body during infusion at the rate Q1, as well as providing 
for rapid attainment of steady state. 
3. For a single infusion at a rate equal to O, two useful equations are 
O = Clp. Cp s (24) 
SS__ A b  -- Va~" C~p s (25) 
In equation 25, A~, s is the amount of drug in the body at steady state. By 
solving both equations 24 and 25 for Cp s and then equating the right-hand 
sides, one obtains 
~_V~.O 
A b - (26) 
C l p  
Thus one could make various estimates of A ~ for different infusion rates Q, 
using tabled mean values of Va~ and Clp. 
Intermittent Bolus Intravenous Therapy 
Approximations for clinical use may be made with equation 17. 
Example 2: Suppose we use the mean tabled val____ues for digoxin (Tables 
IV and IX). These are Di.v. =0.75 mg (750/~g), ~ = 12.9 liters/hr, Vp = 
35.7 liters, Vaext = 944 liters, hi = 0.017 hr -1, and k2 = 1.99 hr -1. Substitut- 
ing these values into equation 17 gives 
Cp = (750/944) e -~176 + (750/35.7)(1 - 35.7/944) e -199` 
= 0.794e-0.017~ + 20.2e-l.99t (27) 
Now, integration of equation 27 between the limits of 0 and 0o gives an 
AUC of 56.9 (ng/ml) • hr. The mean AUC based on 16 data sets (Table VI) 
was 64.3, hence agreement is reasonable. 
Suppose one wished to predict the steady-state level, ~ s ,  and the 
minimum steady-state level, C~p in, if 0.5 mg of digoxin was given as a bolus 
intravenous dose once a day (~" = 24 hr). The steady-state concentration at 
any time t after a dose of 0.5 mg at steady state will be estimated by equation 
28, in which the coefficients have been corrected for dose. 
C, = (0.5/0.75)[0.794/(1 - e-(~176 e-O.017t -t- (0.5/0.75) 
X[20.2/(1 - e - (199) (24 ) ) ]  e -1"99t 
= 1 . 5 8 0 e  -~176  + 1 3 . 5 e  -1"99t (28) 
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The average steady-state level is given by 
C~p S = Di.v./(Clp" r) = 500/(12.9 x 24) = 1.61 ng/ml (29) 
Cp S is also given by the more difficult equation 30: 
fo = c 2 at~, = [ ( 1 . 5 8 0 / 0 . 0 1 7 ) ( 1  - e -(~176 + ( 1 3 . 5 / 1 . 9 9 )  
x (1 - e -('99)(24))]/24 
= 1.58 ng/ml (30) 
The discrepancy in the "answers" given by equations 29 and 30 does 
not reside in the equations, but rather in the fact that the "answer" was 
obtained using mean values of Vp and Vaext, while the other "answer" was 
obtained using the mean value of Ctp. For clinical purposes, the discrepancy 
is not important. 
The minimum plasma level at steady state is estimated with 
rnin _ C~, - 1.580e -(0"017)(24) -t- 13.5e -(1"99)(24) ----- 1.05 ng x ml (31) 
Equation 31 was obtained from equation 28 by letting t = ,. One must be 
aware that such estimates are based on average parameter values and that 
parameter values for individual patients and subjects are not the same. In 
addition, with digoxin, one must be aware that with oral dosing there is the 
additional variable of the fraction of an oral dose which is absorbed. 
Estimation of CIj, for a Particular Patient 
Suppose the tabled Va . . . .  (mean value) has a reasonably small coeffi- 
cient of variation (C.V.) and one has some method of estimating A1 with 
endogenous creatininr clearance, such as given by Wagner (33), or from a 
correlation of h/z with serum creatine concentration, then obtaining )t, with 
equation 11. Then one can estimate the clearance for a particular patient 
from 
C l p  = V d a r e  a " h I (32) 
The range of possible values could be estimated using the estimated range of 
Vd . . . .  obtained with 
Estimated range o f  Vdare a = Vdare a "1" 2 ( C . V . ( % ) / 1 0 0 ) (  V d . . . .  ) (33) 
Use of Vdex, as an Estimate of Yd,,,e, 
Vaex, may be estimated from the dose and terminal log-linear plasma 
concentrations, hence is much easier to obtain experimentally than Vdar~a, 
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which requires sampling at sufficient points to define the entire Cp, t curve 
after a single dose. Hence, for those drugs such as nortriptyline, tranexamic 
acid, warfarin, tobramycin, griseofulvin, pentobarbital, and salicylic acid 
where Vdext is approximately the same as Vd ..... in future studies only Wdext 
really needs to be measured. However, until one knows that these are 
essentially equivalent, use of Vuext is not sound. 
Oral Therapy 
Equation 34 is equivalent to equation 24 when therapy is by the oral 
route. 
Dm/ z = ( CIp/ FF*) C~p ~ (34) 
In equation 34, Dm/'r is the "dose rate," where Dm is the maintenance dose 
and z is the uniform dosing interval; FF* is the "bioavailability factor," 
where F is the fraction of the dose in the dosage form which is absorbed and 
F* is the fraction of that drug absorbed which reaches the general circulation 
as a result of the "first-pass" effect. Hence, to use the Clp values listed in this 
article to make predictions for oral therapy, one must know the value of FF* 
for the particular drug and the particular dosage form of the drug which is 
used. For example, Jusko and Lewis (1) reported that for ampicillin oral 
capsules, sold by Bristol Laboratories, FF* averaged 0.32, with a range of 
0.21-0.46. Work in several laboratories has indicated that the mean value of 
FF* for digoxin tablets, manufactured by Burroughs & Wellcome, is 0.6. 
For warfarin, given in 5-mg tablets, sold by Endo Laboratories, the value of 
FF* is essentially unity (i.e., all the drug is absorbed and there is essentially 
no "first-pass" effect). 
If the Clp values tabled in this report are used, and an estimate of FF* is 
known, then an estimate of the "dose rate" needed to attain a desired 
average steady-state plasma level, C; ,  may be made with equation 34. Once 
the ratio, Dm/z is obtained, then a reasonable value of ~" (i.e., 4, 6, 8, 12, or 
24 hr) and a reasonable value of Dm (i.e., something available from a 
commercial product, such as one tablet, one-half tablet, etc.) are chosen, so 
that one obtains the required "dose rate." Obviously, the smaller the value 
of -r, the less fluctuation there will be in the steady-state levels, i.e., the 
smaller the difference between C-~ ~' and C~ in. 
If oral plasma level data are available, then an estimate of C1JFF* may 
be obtained with equation 35, without knowing the individual values of Clp 
and FF*. In equation 35, Dp.o. is the dose given orally and (AUC)p.o" is the 
total area under the plasma concentration-time curve from zero to infinite 
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t ime after a single dose or the area unde r  the curve dur ing  a dosage interval  
at s teady state. 
C l p / F F *  = Dp.o./(AUC)p.o. (35) 
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